BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24270421)

  • 1. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
    Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
    J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopathy and type 2B von Willebrand disease.
    Ware J
    J Clin Invest; 2013 Dec; 123(12):5004-6. PubMed ID: 24270415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
    Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
    Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction.
    Yuan Y; Dopheide SM; Ivanidis C; Salem HH; Jackson SP
    J Biol Chem; 1997 Aug; 272(35):21847-54. PubMed ID: 9268316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
    Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
    Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
    Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.
    Berrou E; Kauskot A; Adam F; Harel A; Legendre P; Lavenu Bombled C; Rothschild C; Prevost N; Christophe OD; Lenting PJ; Denis CV; Rosa JP; Bryckaert M
    PLoS One; 2015; 10(12):e0143896. PubMed ID: 26645283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.
    Jackson SC; Sinclair GD; Cloutier S; Duan Z; Rand ML; Poon MC
    Blood; 2009 Apr; 113(14):3348-51. PubMed ID: 19060241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner.
    Liu J; Pestina TI; Berndt MC; Jackson CW; Gartner TK
    Blood; 2005 Oct; 106(8):2750-6. PubMed ID: 15985541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
    Casonato A; Gallinaro L; Cattini MG; Pontara E; Padrini R; Bertomoro A; Daidone V; Pagnan A
    Haematologica; 2010 Aug; 95(8):1366-72. PubMed ID: 20305138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
    Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
    J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
    Cooney KA; Ginsburg D
    Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic basis of von Willebrand disease.
    Goodeve AC
    Blood Rev; 2010 May; 24(3):123-34. PubMed ID: 20409624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.